The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

Sanofi (NASDAQ:SNY) said on Thursday its multiple myeloma drug Sarclisa (isatuximab) met the primary endpoints of a late-stage trial. The drug is currently indicated for use in a combination ...

The new approval is a boost for Sanofi because the VRd regimen has become the preferred first-line treatment option for transplant-ineligible multiple myeloma patients in recent years, giving ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in combination with ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

including rare cancers such as multiple myeloma, acute myeloid leukemia, and certain types of lymphomas, as well as gastrointestinal and lung cancers. Sanofi and Orano Med are members of the Paris ...

Sanofi is deepening its commitment to targeted ... including rare cancers such as multiple myeloma, acute myeloid leukemia, and certain types of lymphomas. The scope of the research will also ...

The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's Sarclisa infusion as a treatment for certain types of newly diagnosed multiple ...

NK cell therapy is gaining momentum as a promising solution to unmet medical needs in cancer treatment, offering safer, tar ...